Panbio COVID-19 Antigen Test
GPTKB entity
Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessibility |
aimed at increasing testing availability
|
| gptkbp:approves |
gptkb:World_Health_Organization
|
| gptkbp:availability |
widely available globally
|
| gptkbp:average_temperature |
2-30 degrees Celsius
|
| gptkbp:can_detect |
nasal swab
|
| gptkbp:care_instructions |
included in packaging
|
| gptkbp:clinical_sensitivity |
varies with disease prevalence
|
| gptkbp:clinical_trial |
validated in multiple studies
|
| gptkbp:clinical_use |
rapid testing
|
| gptkbp:developed_by |
gptkb:Abbott_Laboratories
|
| gptkbp:false_negative_rate |
higher in asymptomatic individuals
|
| gptkbp:field_of_use |
public health response
|
| gptkbp:follow-up_testing |
recommended for positive results
|
| gptkbp:historical_interpretation |
visual readout
|
| https://www.w3.org/2000/01/rdf-schema#label |
Panbio COVID-19 Antigen Test
|
| gptkbp:intended_use |
screening for COVID-19 infection
detect SARS-Co V-2 antigens |
| gptkbp:is_tested_for |
contributes to COVID-19 control efforts
lateral flow assay test device, buffer solution, swab |
| gptkbp:manufacturer |
gptkb:Abbott_Laboratories
gptkb:Abbott |
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:packaging |
individually packaged tests
|
| gptkbp:price |
varies by region
|
| gptkbp:regulatory_compliance |
Emergency Use Authorization (EUA)
CE marked emergency use authorization in several countries |
| gptkbp:reliability |
high in symptomatic patients
subject to quality control measures |
| gptkbp:result_time |
15-30 minutes
|
| gptkbp:sampled_in |
nasal swab
nasopharyngeal swab |
| gptkbp:sensitivity |
97.1% (in symptomatic patients)
approximately 97.1% in symptomatic individuals |
| gptkbp:shelf_life |
12 months
|
| gptkbp:specificity |
98.5% (in symptomatic patients)
approximately 98.5% in symptomatic individuals |
| gptkbp:target_virus |
gptkb:SARS-Co_V-2
|
| gptkbp:test_accuracy |
influenced by sample collection technique
|
| gptkbp:test_approval |
approved by WHO for emergency use
|
| gptkbp:test_deployment |
used in various settings including hospitals and clinics
|
| gptkbp:test_distribution |
distributed through various channels
|
| gptkbp:test_effectiveness |
depends on local epidemiology
|
| gptkbp:test_efficacy |
effective for early detection of infection
|
| gptkbp:test_guidelines |
follow manufacturer instructions for use.
|
| gptkbp:test_limitations |
not for self-testing
|
| gptkbp:test_performance |
depends on timing of sample collection
|
| gptkbp:test_performance_evaluation |
ongoing assessments conducted
|
| gptkbp:test_recommendations |
recommended for symptomatic individuals
|
| gptkbp:test_reporting |
results reported to health authorities
|
| gptkbp:test_result_categories |
positive, negative, invalid
|
| gptkbp:test_results_interpretation |
requires professional judgment
|
| gptkbp:test_safety |
considered safe for use in clinical settings
|
| gptkbp:test_usage_guidelines |
follow local health regulations
|
| gptkbp:test_validation |
conducted in various populations
|
| gptkbp:time_to_result |
15-30 minutes
|
| gptkbp:training |
minimal training required
|
| gptkbp:type |
antigen test
|
| gptkbp:usage |
screening for active COVID-19 infection
|
| gptkbp:user |
gptkb:healthcare_professionals
|
| gptkbp:uses |
nasopharyngeal swab
|
| gptkbp:year_established |
gptkb:2020
|